Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply